Please assess the completion status of the following clinical trial:

Trial Title: 36 mm Ceramic-on-Ceramic Acetabular Cup Total Hip Replacement

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Non-inflammatory degenerative joint disease. Composite diagnoses of NIDJD include osteoarthritis, avascular necrosis, post-traumatic arthritis, slipped capital femoral epiphysis (SCFE), fracture of the pelvis, and developmental dysplasia.~* X-ray evaluation confirms the presence of NIDJD~* Femoral and acetabular bone stock is sufficient, regarding strength and shape, and is suitable to receive the implants.~* Individuals 20 to 75 years of age at the time of surgery~* Patients with a previous total hip replacement of the contralateral leg who have a pain rating of none or slight and who are at least one year post arthroplasty are eligible for participation in the study.~* Harris Hip Score of 70 or lower~* Pain at least Moderate~Exclusion Criteria:~* Presence of a previous prosthetic hip replacement device (any type, including surface replacement arthroplasty, endoprosthesis, etc.) in the hip joint to be operated.~* Previous Girdlestone procedure (resection arthroplasty) or surgical fusion of the hip to be operated.~* Acute femoral neck fracture.~* Above knee amputation of the contralateral and/or ipsilateral leg.~* Patients with bilateral degenerative joint disease requiring staged or simultaneous hip replacements.~* Patients with an existing total hip arthroplasty in the contralateral hip with a Harris Hip pain rating of mild, moderate, marked or totally disabled.~* Patients who have undergone total hip arthroplasties in their contralateral hips within the past 12 months.~* Patients with a known allergy to metal (e.g. jewelry).~* Skeletally immature patients (tibial and femoral epiphyses are not closed).~* Evidence of active infections that may spread to other areas of the body (e.g., osteomyelitis, pyogenic infection of the hip joint, overt infection, urinary tract infection, etc.).~* The presence of highly communicable disease or diseases that may limit follow-up (e.g., immuno-compromised conditions, hepatitis, active tuberculosis, etc.).~* Presence of known metastatic or neoplastic disease.~* Significant neurologic or musculoskeletal disorders or disease that may adversely affect gait or weight bearing, (e.g., muscular dystrophy, multiple sclerosis).~* Conditions that may interfere with the total hip arthroplasty's survival or outcome, (e.g., Paget's disease, Charcot's disease).~* Any patient believed to be unwilling or unable to comply with a rehabilitation program for a cementless total hip replacement or who indicates difficulty or inability to return for follow-up visits prescribed by the study protocol.~* Patient is known to be pregnant, a prisoner, mentally incompetent, and/or alcohol or drug abuser.~* Any systemic steroid therapy, excluding inhalers, within three months prior to surgery.~* Patients carrying the diagnosis of inflammatory degenerative arthritis (IDJD) to include the following composite diagnoses: rheumatoid arthritis, systemic lupus erythematosus, pigmented villonodular synovitis, juvenile rheumatory arthritis and other arthritic processes of inflammatory or autoimmune etiology.~* Patients requiring structural bone grafts in order to support the prosthetic component(s) or to shape the bone to receive the implant(s).~* Patients who refuse to provide consent to participate in the clinical investigation.~* Surgical replacement requires the use of an acetabular liner and femoral head greater or smaller than a 36mm diameter

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 36 mm (Type: ACTIVE_COMPARATOR): 36 mm ceramic head on ceramic acetabular liner
- 28 mm ceramic-on-polyethylene (Type: OTHER): 28 mm ceramic-on-polyethylene historical control

Based on this trial design, predict the completion outcome and termination type (if applicable).